Randomised controlled trial of surveillance and no surveillance for patients with Barrett's oesophagus

Submission date	Recruitment status	[X] Prospectively registered		
27/12/2007	No longer recruiting	[X] Protocol		
Registration date	Overall study status	Statistical analysis plan		
08/01/2008 Last Edited	Completed Condition category	Results		
		Individual participant data		
01/07/2022	Digestive System	Record updated in last year		

Plain English summary of protocol

http://www.cancerhelp.org.uk/trials/a-trial-looking-at-how-often-to-monitor-people-with-barretts-oesophagus

Contact information

Type(s)

Scientific

Contact name

Prof Hugh Barr

Contact details

Gloucestershire Royal Hospital Great Western Road Gloucester United Kingdom GL1 3NN

_

hugh.barr@nhs.net

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

NCT00987857

Secondary identifying numbers

HTA 05/12/01

Study information

Scientific Title

Randomised controlled trial of surveillance and no surveillance for patients with Barrett's oesophagus: BOSS (Barrett's Oesophagus Surveillance Study)

Acronym

BOSS

Study objectives

Comparison of endoscopic surveillance verus no endoscopic surveillance for the prevention of early mortality and the development of oesophageal adenocarcinoma.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Submission pending as of 02/01/2008

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Screening

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Barrett's oesophagus

Interventions

Upper gastrointestinalendoscopy every 2 years for 10 years

Intervention Type

Procedure/Surgery

Primary outcome measure

- 1. All causes mortality
- 2. Death from adenocarcinoma
- 3. Development of treatable adenocarcinoma

Duration of follow-up: 10 years

Secondary outcome measures

- 1. Quality of life: Reflux Questionnaire and EQ50 Quality of Life Questionnaire at yearly intervals by post
- 2. Cost effectiveness of endoscopy

Overall study start date

01/09/2009

Completion date

30/06/2022

Eligibility

Key inclusion criteria

Patients over 18 with endoscopic and histologically proven barrett's oesophagus greater than 1 cm

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

2,500

Total final enrolment

3520

Key exclusion criteria

- 1. Unable to give consent
- 2. Unable to tolerate upper gastrointestinal endoscopy

Date of first enrolment

01/09/2009

Date of final enrolment

30/06/2022

Locations

Countries of recruitment

England

United Kingdom

Study participating centre
Gloucestershire Royal Hospital
Gloucester
United Kingdom
GL1 3NN

Sponsor information

Organisation

Gloucestershire Royal NHS Foundation Trust (UK)

Sponsor details

Research and Development Support Unit Great western Road Gloucester England United Kingdom GL1 3NN +44 (0)8454 226679 hugh.barr@glos.nhs.uk

Sponsor type

Hospital/treatment centre

ROR

https://ror.org/04mw34986

Funder(s)

Funder type

Government

Funder Name

Health Technology Assessment Programme

Alternative Name(s)

NIHR Health Technology Assessment Programme, HTA

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

Not provided at time of registration

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article	protocol	01/09/2015		Yes	No